{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:40:43Z","timestamp":1792449643855,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bioorg.2023.106966","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:29:51Z","timestamp":1699702191000},"page":"106966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD\/D835Y and FLT3-ITD\/F691L secondary mutants"],"prefix":"10.1016","volume":"143","author":[{"given":"Xiuqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Anna","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuet-Kin","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10147","key":"10.1016\/j.bioorg.2023.106966_b0005","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bioorg.2023.106966_b0010","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106966_b0015","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of FLT3-ITD length on prognosis of acute myeloid leukemia","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.bioorg.2023.106966_b0020","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2023.106966_b0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bioorg.2023.106966_b0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.bioorg.2023.106966_b0035","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bioorg.2023.106966_b0040","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106966_b0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106966_b0050","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2023.106966_b0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bioorg.2023.106966_b0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V120.21.673.673","volume":"120","author":"Levis","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bioorg.2023.106966_b0065","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmcl.2009.07.024","article-title":"Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors","volume":"19","author":"Patel","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.bioorg.2023.106966_b0070","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2023.106966_b0075","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7397","key":"10.1016\/j.bioorg.2023.106966_b0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bioorg.2023.106966_b0085","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bioorg.2023.106966_b0090","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.bioorg.2023.106966_b0095","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bioorg.2023.106966_b0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cGatekeeper\u201d F691L Mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bioorg.2023.106966_b0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00894-022-05254-0","article-title":"Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy","volume":"28","author":"Zhou","year":"2022","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bioorg.2023.106966_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082312","article-title":"Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions","volume":"15","author":"Fedorov","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.bioorg.2023.106966_b0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS Pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.bioorg.2023.106966_b0120","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways","volume":"109","author":"Piloto","year":"2007","journal-title":"Blood"},{"issue":"5405","key":"10.1016\/j.bioorg.2023.106966_b0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"5682","key":"10.1016\/j.bioorg.2023.106966_b0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106966_b0135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.bioorg.2023.106966_b0140","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bioorg.2023.106966_b0145","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/blood-2008-04-149286","article-title":"Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group","volume":"112","author":"Burmeister","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106966_b0150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bioorg.2023.106966_b0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2023.106966_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.588876","article-title":"Emergence of BCR-ABL1 fusion in AML Post-FLT3 inhibitor-based therapy: a potentially targetable mechanism of resistance \u2013 a case series","volume":"10","author":"Alotaibi","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2023.106966_b0165","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41379-018-0014-x","article-title":"Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome","volume":"31","author":"Kurt","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2023.106966_b0170","first-page":"7","article-title":"Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets","volume":"5","author":"Kasi","year":"2016","journal-title":"Leuk Res. Rep."},{"key":"10.1016\/j.bioorg.2023.106966_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejmech.2015.02.052","article-title":"Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors","volume":"94","author":"Frett","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106966_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106966_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.12.033","article-title":"Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC","volume":"109","author":"Peng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106966_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114792","article-title":"Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)","volume":"243","author":"Reznickova","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2023.106966_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051113","article-title":"An Orally Bioavailable and highly efficacious inhibitor of CDK9\/FLT3 for the treatment of acute myeloid leukemia","volume":"14","author":"Anshabo","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bioorg.2023.106966_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2021.100830","article-title":"Synergistic cytotoxicity of dual PI3K\/mTOR and FLT3 inhibition in FLT3-ITD AML cells","volume":"82","author":"Darici","year":"2021","journal-title":"Adv. Biol. Regul."},{"issue":"14","key":"10.1016\/j.bioorg.2023.106966_b0205","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2023.106966_b0210","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03445","article-title":"Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy","volume":"3","author":"Warkentin","year":"2014","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.bioorg.2023.106966_b0215","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106966_b0220","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106966_b0225","doi-asserted-by":"crossref","first-page":"e19169","DOI":"10.1371\/journal.pone.0019169","article-title":"Survey of activated FLT3 signaling in leukemia","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bioorg.2023.106966_b0230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/A:1009623222534","article-title":"Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells","volume":"5","author":"Fernandez-Luna","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.bioorg.2023.106966_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114964","article-title":"Bcr-Abl drives the formation of Hsp70\/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis","volume":"198","author":"Zhang","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106966_b0240","unstructured":"X. Wang, R.A. DeFilippis, T.G. Weldemichael, N. Gunaganti, P. Tran, Y.K. Leung, N.P. Shah, H. Li, An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD\/F691L., manuscript submitted for publication."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823006272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:46:51Z","timestamp":1758617211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823006272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"alternative-id":["S0045206823006272"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106966","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD\/D835Y and FLT3-ITD\/F691L secondary mutants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106966"}}